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Abstract
Use of ‘smart drugs’ among UK students is described in frequent media reports as a rapidly increasing phenomenon. This
article reports findings from the first large-scale survey of pharmacological cognitive enhancement (PCE) among students in
the UK and Ireland. Conducted from February to September 2012, a survey of a convenience sample of 877 students
measured PCE prevalence, attitudes, sources, purposes and ethics. Descriptive and logistic regression statistical methods
were used to analyse the data. Lifetime prevalence of PCE using modafinil, methylphenidate or Adderall was under 10%,
while past regular and current PCE users of these substances made up between 0.3%–4% of the survey population. A
substantial majority of students was unaware of and/or uninterested in PCE; however about one third of students were
interested in PCE. PCE users were more likely to be male, British and older students; predictors of PCE use included
awareness of other students using PCEs, ADHD symptomatology, ethical concerns, and alcohol and cannabis use. The
survey addresses the need for better evidence about PCE prevalence and practices among university students in the UK. We
recommend PCE-related strategies for universities based on the survey findings.
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Introduction
Prevalence of pharmacological cognitive enhancement
The past five years have seen increasing debate about cognitive
enhancement, emerging initially in the United States and then
more recently in the United Kingdom and Europe. A general
definition of cognitive enhancement is provided in Hildt & Franke
[1]:
Cognitive enhancement is the use of drugs, biotechnological
strategies or other means by healthy individuals aiming at
the improvement of cognitive functions such as vigilance,
concentration or memory without any medical need. [1:2].
The use of prescription drugs for non-medical purposes has
driven some of the controversy over cognitive enhancement. The
academic literature on pharmacological cognitive enhancement
(PCE) has focused primarily on three pharmacological substances:
methylphenidate (e.g. Ritalin) and its related compounds; mixed
amphetamine salts, traded in the United States under the name
Adderall; and modafinil (Provigil). Methylphenidate and mixed
amphetamine salts are psychostimulants, and are the most
common forms of pharmacological treatment for Attention
Deficit/Hyperactivity Disorder (ADHD). Modafinil is used as a
treatment for narcolepsy.
PCE has invoked increasing media scrutiny in many countries
around the world [2–4], with special emphasis placed on the non-
medical use of prescription drugs by university students. Several
national ethics advisory bodies have addressed PCE (5), including
the US President’s Council on Bioethics, the UK Parliament, and
the Italian National Bioethics Commission [6–8].
A salient topic in the debate is non-medical use of prescription
drugs as ‘smart drugs’ or ‘study aids’ among university students.
PCE prevalence data is available primarily from research among
US university students, in which estimates of non-prescription
stimulant drug use range from 5%–35% [9–10], with members of
fraternities and sororities often showing the highest rates [11].
Documentation of PCE prevalence in Europe has been both less
systematic and less comprehensive than in the US. Looking across
a range of different studies, PCE prevalence estimates in different
EU Member States range from 0.8% to 16%, depending on
country, university and type of drug used [12–19]. Moreover,
variation in study sample and methods, and research design
quality, complicates comparative understanding of PCE preva-
lence across the EU [20].
Research on PCE prevalence in the UK is particularly sparse.
The only published study to date is an investigation of prescription
drug abuse that includes PCE as one form of drug misuse. From a
sample of 1614 students and 489 university staff at a university in
Wales [19], a total of 37 students (0.02%) reported having used
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stimulant drugs without a prescription; of these respondents, three
reported having used prescription stimulants in order to study.
The other source of systematic evidence available on PCE
prevalence in the UK derives from a population survey conducted
by the Wellcome Trust (http://www.wellcome.ac.uk/About-us/
Publications/Reports/Public-engagement/WTX058859.htm). The
Wellcome Monitor, which included seven questions on cognitive
enhancement, found low PCE prevalence in the general population.
Approximately 2% of adult respondents and 1% of young people
aged 14–18 admitted to PCE using Ritalin or Adderall. No
respondents had used modafinil for PCE. One third of both adults
and young people held that regular or occasional use of pharmaco-
logical cognition enhancement was acceptable.
In the absence of research evidence, journalism is the most
widely cited source of information about UK PCE prevalence. In
2009 the student newspaper at Cambridge University, The Varsity,
surveyed 1000 students and found a 10% PCE prevalence rate.
The survey queried students about ‘‘taking medication without
prescription to help them work’’ [21]. Information about the
survey is limited to a short article in the student paper.
Limitations of PCE survey evidence
While large-scale surveys of PCE can in principle provide us
with a high level understanding of PCE prevalence, published
PCE surveys tend to have several limitations. Prevalence data are
often misrepresented because drug use practices and purposes are
not elicited as part of the survey. Drug use practices are important
because lifetime prevalence can easily be misrepresented as
frequent and on-going use when an individual has in fact used
the drug only once or twice. In turn, this can lead to overestimates
of current PCE prevalence, and can help to foster a false picture of
PCE as a widespread and ongoing practice [20]. Drug use
purposes are also important to distinguish in a PCE survey. As
Partridge [22] has argued, reported misuse of prescription
stimulants is often assumed to mean that misuse is aimed
specifically at cognition enhancement, when the true purpose
may instead be recreational.
Surveys have rarely investigated the ethical dimensions of PCE.
Evidence from qualitative studies in the US suggests that PCE
users tend to conceive of PCE as being both safe and morally
unproblematic [23–25]. A small interview study among German
university students found that ethical considerations were a
relatively low priority in PCE decision-making. Medical and legal
dimensions played a more important role than ethical consider-
ations in students’ reasoning about the use of caffeine as a ‘smart
drug’ as compared to PCE [26]. Two studies with Cambridge
University students found that participants condemned PCE when
there were long-term negative effects on health and when PCE
was seen to confer an unfair advantage in exam situations [27].
Rationale for the current study
Despite the lack of evidence for PCE prevalence in the UK,
there is an increasing level of concern and activity around PCE,
encouraged in the media and extending to public debate and
Parliamentary and Home Office activity [28]. Within these
debates, prevalence estimates for PCE in the UK are derived
from poor quality sources, as outlined above. Characteristics of
UK PCE users and practices, as well as PCE sources, are the
subject of widespread speculation [3]. Attitudes toward PCE in the
UK also lack systematic investigation.
The aim of the current study was to conduct a national survey of
PCE among UK and Irish university students in order to gain
better understanding of PCE in a population hypothesized to be
active PCE users.
Methods
A survey of a convenience sample of students enrolled in
universities in the UK and Ireland was conducted from February
to September 2012. Participants were recruited using on-line
methods, including social media sites and national university
student mailing lists.
The survey was developed on the basis of a review of the
available empirical studies of PCE, as well as a series of focus
groups involving 70 university students. Before launching, the
survey was piloted with 13 university students and questions were
revised on the basis of their feedback. The final survey included
measures of knowledge of smart drugs, drug use patterns
(prevalence, last-year and last-month prevalence, drug use
motivations and frequency), eventual prescription use of cognition
enhancers (which also included questions about non-prescribed
ways of use as well as diversion), questions on ethics, and two
psychological instruments: the 6-item World Health Organisation
(WHO) version of the Adult ADHD Self-report Scale (http://
www.hcp.med.harvard.edu/ncs/asrs.php) and the Rosenberg Self-
Esteem Scale (https://personality-testing.info/tests/RSE.php).
The survey was conducted using Surveygizmo (www.
surveygizmo.com) under a domain (www.thesmartdrugstudy.
com) purchased and set up for the purposes of the project.
Respondents were presented with the following definition:
Smart drugs, also known as cognitive enhancers, are
prescription and non-prescription substances that people
use to improve their cognitive functioning and performance.
From a list containing 27 substances (in randomized order)
respondents were asked to mark those they considered to be ‘smart
drugs’ based on the above definition; they also had the option to
enter additional drugs into a textbox if they considered an
important substance to be missing from the list. For the purposes
of this study we considered the following drugs to be cognition
enhancers: methylphenidate, modafinil, Adderall, donepezil,
piracetam, and atomoxetine.
When assessing drug use prevalence we distinguished among 6
different categories of use for each of the 27 drugs listed on the
survey:
1) I have never heard of it
2) I never tried it and was never interested
3) I never tried it but considered doing so
4) I tried it a few times in the past
5) I used it regularly in the past
6) I use it nowadays
To differentiate substance use groups, we created four distinct
and mutually exclusive categories of user groups for the most
commonly identified PCEs (modafinil, methylphenidate and
Adderall).
1) Respondents who indicated that they had never heard of, or
that they were not interested in methylphenidate, modafinil
and Adderall
2) Respondents who indicated their interest in at least one of
three substances but had never tried any of the them
3) Respondents who had used methylphenidate, modafinil, or
Adderall but not for the purpose of enhancing cognitive
performance (non-PCE-type use)
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4) Respondents who had used at least one smart drug for the
purpose of enhancing cognitive performance (PCE users).
To obtain a detailed understanding of drug use purposes,
respondents were asked to indicate all the relevant motivations for
using each substance, by choosing from a list containing 18 options
or entering their individual answer into an open-ended textbox.
We asked those respondents who indicated an interest in
modafinil, methylphenidate or Adderall, but who had not actually
used these substances, to provide reasons why they had not used
the drugs in question. Respondents described their reasons in a
text-entry box on the survey. Answers were coded by two
independent coders into 14 previously agreed categories (see
www.thesmartdrugstudy.com for further information). When
respondents gave several reasons why interest had not converted
to use, each reason was individually coded and categorised. When
responses were coded into different categories by the two coders,
then the final result is the rounded-up average of the two coders’
results.
Respondents were asked whether PCE use by students in an
academic setting is ethically problematic. Three more specific
questions were also asked: whether PCE use by students is like
doping in sports, whether PCE use by students constitutes
cheating, and if students feel pressure to use PCEs at university.
A Likert-type scale was used to query respondents on ethical issues.
Responses on each question were analysed for the four PCE user-
types described earlier.
Statistical analysis was conducted using Stata 11, generating
standard cross-tabulations, frequency tables and mean compari-
sons.
We also fitted a series of multinomial logistic regression models
to examine the predictors of drug usage for modafinil, methyl-
phenidate, Adderall and caffeine, in which we differentiated
among the four user groups identified above. We used ordinal
logistic (or proportional odds) modelling to estimate the factors
associated with moving up or down the four user group categories
for each drug. The potential predictors were: gender, age (17–20,
21–24, 25–29 and 30+), ethnicity (White British, other White, and
non-White), alcohol use, cannabis use, awareness of other people
at university using smart drugs, ADHD score, self-esteem score,
and beliefs about the ethics of using smart drugs to improve
academic performance.
The statistical technique groups adjacent values of the ordinal
response into two groups, ‘‘high" (i.e. higher-numbered) and
‘‘low", divided at each level j = 1;:::;C-1 in turn. For drug use and
awareness, there are three such groupings:
Table 1. Participant characteristics (n= 877).
% n
Gender
Male 46% 403
Female 53% 467
Not recorded 1% 7
Degree
Undergraduate 75% 660
Postgraduate 22% 192
Other 3% 25
doi:10.1371/journal.pone.0105969.t001
Table 2. What is a smart drug? (n= 877).
Substance % of respondents identifying it as a smart drug Substance % of respondents identifying it as a smart drug
1. caffeine pills 42.1% 15. LSD 6.2%
2. methylphenidate 41.5% 16. MDMA 5.7%
3. energy drinks 33.9% 17. DMT 4.3%
4. vitamin supplements 29.2% 18. magic mushrooms 4.3%
5. modafinil 25.9% 19. sleeping pills 4.2%
6. Adderall 25.3% 20. Relevin 3.9%
7. speed 22.4% 21. crystal meth 3.8%
8. piracetam 13.1% 22. mephedrone 3.3%
9. ephedrine 9.2% 23. alcohol 2.6%
10. marijuana 9.3% 24. pain killers 2.6%
11. donepezil 8.9% 25. ketamine 2.5%
12. tobacco 8.3% 26. tranquilizers 22.2%
13. cocaine 7.8% 27. heroin 1.5%
14. atomoxetine 6.8%
doi:10.1371/journal.pone.0105969.t002
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N used [high] vs. (considered, uninterested, unaware) [low]
N (used, considered) [high] vs. (uninterested, unaware) [low]
N (used, considered, uninterested) [high] vs. (unaware) [low]
The regression coefficient of an explanatory variable X is then
interpreted as the log odds ratio (and its exponential as the odds
ratio) associated with a one-unit increase in X, for the choice of the
high rather than low value in these dichotomies, with the same
odds ratio applied to each way of grouping the response levels.
Blocks of variables were added one at a time resulting in six models
(Model I includes demographic variables, Model II adds alcohol
use and cannabis use, Model III adds awareness of other people at
university using smart drugs, and so on) to assess the effect of
incrementally adjusting for other factors.
The proportional odds assumption was tested using the Brant
test [29]. The test indicated no problems for all variables but the
‘beliefs about the ethics of using smart drugs to improve academic
performance’ variable, added in Model VI for each of the drugs.
Because the other predictors in the fitted ordered logistic models
conformed to the proportional odds assumption, and because the
findings from the multinomial logistic regression models indicated
the same pattern of relationships, (controlling for ethical beliefs),
we proceed with discussion of results from this analysis. We also
interpret the results from the fitted multinomial logistic regressions
when it comes to beliefs about the ethics of using smart drugs to
improve academic performance in light of the Brant test.
Results
The final sample size was 877. Two respondents who completed
the survey were excluded because they reported taking a fake drug
called ‘Relevin’ [30]. We also dropped 14 respondents from the
sample who said they had used cognitive enhancers for a medical
indication and had a legitimate prescription.
Table 1 outlines the demographic profile of the sample. 75% of
students in the sample reported being undergraduates. Participa-
tion was almost equally split between males and females. The
mean age of participants was 22.7 years old. Participants were
drawn from 104 universities in the UK and Ireland; a majority of
respondents (79%) reported enrolment at a Russell Group
university. The Russell Group is an association of the leading
research universities in the United Kingdom. Our sample includes
students from 23 of the 24 Russell Group member institutions.
Universities most frequently represented in the survey were: Bristol
University (n= 161), Manchester University (n= 96), Cardiff
University (n= 88), London School of Economics (n= 86), Cam-
bridge University (n= 77), Oxford University (n= 34) and
University College London (n= 32).
Smart drugs
The five substances most frequently identified as ‘smart drugs’
were caffeine pills, methylphenidate, energy drinks, vitamin
supplements, and modafinil (See Table 2 below for complete list).
A small proportion of the sample (2%) was able to identify all 6
substances our study considered to be cognition enhancers, while
44% of respondents identified none as a smart drug.
PCE prevalence
We measured lifetime prevalence for the three prescription
drugs most commonly used for PCE (methylphenidate, modafinil
and Adderall). We also conducted a comparative analysis with
Table 3. Smart Drug Prevalence (n = 877).*
methylphenidate n (%) modafinil n (%) Adderall n (%) caffeine pills n (%)
Unaware 154 (17.6%) 514 (58.6%) 434 (49.5%) 13 (1.5%)
Uninterested 507 (57.8%) 213 (24.3%) 304 (34.7%) 302 (34.4%)
Considered 164 (18.7%) 80 (9.1%) 110 (12.5%) 129 (14.7%)
Past occasional PCE use 22 (2.5%) 18 (2.1%) 12 (1.4%) 109 (12.4%)
Other use 15 (0.7%) 10 (1.1%) 7 (0.8%) 141 (16.1%)
Past regular PCE use 6 (1%) 6 (0.7%) 3 (0.3%) 49 (5.6%)
Other use 2 (0.2%) 2 (0.2%) 2 (0.2%) 43 (4.9%)
Current PCE use 7 (0.8%) 30 (3.4%) 3 (0.3%) 55 (6.3%)
Other use 0 (0%) 4 (0.5%) 2 (0.2%) 36 (4.1%)
*Table 3 contains synthesized information from two questions. Prevalence – based on the six options listed – and purposes, focusing on PCE. Respondents could
choose from 17 other purposes besides PCE; a subset of the data on other purposes is reported in Table 4. ‘PCE use’ was defined as a respondent who indicated PCE
alone or in any combination; ‘other use’ was defined as a respondent who did not indicate PCE, but did indicate any other purpose.
doi:10.1371/journal.pone.0105969.t003
Table 4. Drug use purposes for modafinil, methylphenidate, Adderall and caffeine pills, as reported by users of these substances.
Substance Users Enhance Cognition n (%) Offset sleep deprivation n (%) Enhance mood n (%) Curiosity n (%)
modafinil, n= 70 54 (77.1%) 43 (61.4%) 12 (17.1%) 15 (21.4%)
methylphenidate, n= 52 35 (67.3%) 14 (26.9%) 10 (19.2%) 19 (36.5%)
Adderall, n=28 18 (64.3%) 8 (28.6%) 6 (21.4%) 13 (46.4%)
caffeine pills, n= 432 213 (49.3%) 265 (61.3%) 46 (10.6%) 35 (8.1%)
Note that respondents could select more than one purpose for each drug.
doi:10.1371/journal.pone.0105969.t004
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caffeine, which a majority of students identified as a cognitive
enhancer. Table 3 presents the breakdown for these four
substances.
Lifetime prevalence for methylphenidate was 5.9%. The drug
was unknown to almost 18% of our sample; 19% had considered
trying it and 58% reported that they had never had interest in
trying it. About 4% of users had taken methylphenidate for PCE,
while about 1% had taken it for non-PCE use.
Modafinil was simultaneously the most unknown and the most
frequently used cognition enhancer. Lifetime prevalence for
modafinil was 8%. Lifetime prevalence for PCE use was 6.2%,
which suggests that modafinil was used primarily for PCE
purposes by this sample of students. Almost 59% of students had
never heard of modafinil, while about 24% said they were never
interested in trying it. Nine percent of students had considered
trying modafinil.
Lifetime prevalence for Adderall was 3.2% overall and 2% for
PCE use. Around 50% of respondents were unaware of Adderall;
over a third were uninterested in it; and about 13% had
considered using the drug.
In the case of the psychostimulants (methylphenidate and
Adderall) there was a marked difference between the number of
respondents who had tried the drug in the past and those who
were current users. Respondents were five times more likely to be
past users of methylphenidate than current users. Similarly,
respondents were four times more likely to be past users of
Adderall than current users. Modafinil use patterns differed from
methylphenidate and Adderall use patterns; there was a slightly
higher number of current users than past users of modafinil.
In comparison with the prescription medications, the lifetime
prevalence for caffeine pills was 49.4%, with 24.3% lifetime
prevalence for cognitive enhancement. A very small proportion of
respondents were unfamiliar with caffeine pills (1.5%), while over
10% identified as current users, with current users choosing
caffeine pills for cognitive enhancement than for other purposes.
Drug use motivations
Table 4 shows four of the most commonly indicated drug use
motivations for modafinil, methylphenidate, Adderall and caffeine
pills, by users of these substances (note that respondents could
indicate more than one reason).
All four substances were used, to varying degrees, to ‘enhance
cognition’, ‘offset sleep deprivation’, and to ‘enhance mood’. Not
included in Table 4 are the substances that were most commonly
used to ‘enhance cognition’ and to ‘offset sleep deprivation’ by
students in the sample as a whole (n = 877). These substances were
energy drinks and caffeine tablets: 30% of the total sample had
used energy drinks to enhance cognition; 45% had used energy
drinks to offset sleep deprivation; 24% had used caffeine tablets to
enhance cognition; 30% had used caffeine tablets to offset sleep
deprivation.
User groups characteristics
Considering methylphenidate, Adderall and modafinil together,
two thirds of the sample was not interested in these drugs for any
purpose. This category was broken down into three further
groups. Fourteen percent of respondents said that they had never
heard of any of the three smart drugs. Another 14.5% of students
responded that they were never interested in any of the three
drugs. The remaining 38% of respondents in this category were
unaware of some, and uninterested in the other, substances.
Around 20% of students had considered using at least one of the
three drugs, and 9.4% of the sample had used one of these drugs to
improve cognitive performance at least once. About 3% of
respondents had used one of these three drugs for purposes other
than cognitive enhancement. Table 5 details this breakdown of the
results.
Table 5. n=877. User group categories on the basis of familiarity with methylphenidate, modafinil and Adderall.
User groups n (%)
Unaware/not interested Unaware of all PCEs 123 (14.0%)
Uninterested in all PCEs 127 (14.5%)
Unaware of some of the PCEs and uninterested in the other PCEs 336 (38.3%)
Considered using at least one PCE 179 (20.4%)
Non-CE type user (at least one drug) 30 (3.4%)
PCE-type user (at least one drug) 82 (9.4%)
doi:10.1371/journal.pone.0105969.t005
Table 6. ADHD ASRS Score by user group, n= 877.
User groups Mean Std. Err. 95% confidence interval
Unaware/not interested Unaware of all PCEs 2.4 0.1 2.2 2.7
Uninterested in all PCEs 2.4 0.1 2.1 2.7
Unaware of some of the PCEs and uninterested in the
other PCEs
2.6 0.1 2.4 2.7
Considered using at least one PCE 3.1 0.1 2.9 3.3
Non-CE type user (at least one drug) 3.1 0.3 2.4 3.7
PCE-type user (at least one drug) 2.7 0.2 2.3 3.1
doi:10.1371/journal.pone.0105969.t006
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Self-reported ADHD-symptoms
In this sample, none of the four drug user groups received a
score consistent with clinically significant symptomatology of adult
ADHD (see Table 6).
Conversion from interest in PCEs to use of PCEs
Table 7 details the three most common reported reasons given
by respondents for why their interest in modafinil, methylpheni-
date and Adderall for PCE purposes did not convert to substance
use. Lack of availability was the most common reason why
interested students had not yet tried one of these three drugs,
particularly in the case of the stimulant drugs. About half of
students interested in PCE using stimulants cited lack of
availability as the reason interest had not converted to use.
Not shown in the table is the finding that lack of availability was
given as the sole reason why interest did not convert to use in a
majority of cases (in 61/83 [74%] cases for methylphenidate, in
18/28 [64%] cases for modafinil, and in 40/56 [71%] cases for
Adderall). The next most frequently cited reasons for non-
conversion of interest to use were concerns about side effects,
and concerns about the illegality of use.
Successful access to the stimulants (methylphenidate and
Adderall), and modafinil was achieved via diverse routes. Adderall
and methylphenidate were obtained primarily from friends.
Modafinil was sourced primarily from an on-line distributor, such
as an on-line pharmacy. Table 8 provides an overview of findings
on the sources of PCEs.
Ethics
The results of the broad ethics question are summarised in
Table 9. Views on the ethics of PCE in academia were related to
respondents’ experience of and attitudes toward PCEs. Among
those who were unaware of, or uninterested in, modafinil,
Adderall and methylphenidate, 13% were neutral and a majority
(69.2%) agreed or strongly agreed that PCE in academic contexts
is ethically problematic. Respondents who had considered PCE, or
who had used PCEs, found PCE in academia to be less
problematic. Among respondents who had considered PCE,
20% were neutral about the ethics of PCE use in academia, and
almost 45% agreed or strongly agreed that PCE use in academia
was problematic. Among PCE users, about 16% were neutral and
almost 21% agreed or strongly agreed that PCE use in academia is
problematic. In comparison to other user groups, the aware but
disinterested group tended to have stronger positive and stronger
negative opinions about the ethics of PCE use in academic settings.
A very small minority (6.4%) of respondents in this group strongly
disagreed that PCE in academia is ethically problematic while just
under half of respondents (45.7%) strongly agreed with the
statement.
Responses to the comparisons between PCE and doping in
sports, and PCE and cheating were similarly dependent on user
group, with those who had considered PCE and those who were
PCE users less likely than the unaware/uninterested respondents
to validate the comparisons. The comparison with cheating drew
the strongest opinions from PCE users, 72% strongly disagreed
with the comparison and no PCE users strongly agreed. Those
who had considered PCE tended to disagree or strongly disagree
that PCE was like cheating (29% and 32% respectively), or like
doping in sports (21% and 22% respectively). About one fifth of
those unaware/uninterested in PCE were neutral on both these
comparisons. About one third of unaware/uninterested respon-
dents disagreed to some extent with the comparison between PCE
and cheating. However, 63% of these respondents endorsed the
comparison between PCE and doping (27% agreed and 36%
strongly agreed), and just under half of these respondents endorsed
the comparison between PCE and cheating (24% agreed and 27%
strongly agreed).
Across all user groups, a majority of respondents disagreed or
strongly disagreed with the statement: ‘‘I would feel pressured to
Table 7. Reasons for not using by those who have considered a PCE.
Considered modafinil but
not tried yet (n=78)
Considered methylphenidate
but not tried yet (n=161)
Considered Adderall but
not tried yet (n=105)
n (%) n (%) n (%)
Lack of availability 28 (35.9%) 83 (51.6%) 56 (53.3%)
Concerns about
side-effects
13 (16.7%) 25 (15.5%) 14 (13.3%)
Illegality 9 (11.5%) 14 (8.7%) 11 (10.5 s%)
Note that only the three most common reasons are shown.
doi:10.1371/journal.pone.0105969.t007
Table 8. Source of PCEs reported by users of these substances.
Source of drug Modafinil n (%) Methylphenidate n (%) Adderall n (%)
Family 0 (0%) 2 (4.1%) 1 (3.6%)
Friends 15 (21.4%) 37 (75.5%) 25 (89.3%)
Drug dealer 0 (0%) 2 (4.1%) 1 (3.6%)
Online 45 (64.3%) 1 (2.0%) 1 (3.6%)
Ambiguous entry 8 (11.4%) 7 (14.3%) 0 (0%)
Total 69 (100%) 49 (100%) 28 (100%)
doi:10.1371/journal.pone.0105969.t008
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use PCEs if I knew other people used them.’’ The frequency of
disagreement diminished as PCE became more of a reality, such
that about 80% of the unaware/uninterested group disagreed or
strongly disagreed with the statement; 53% of the group that had
considered PCE use disagreed or strongly disagreed; and 52% of
PCE users disagreed or strongly disagreed. Across groups, the
highest proportion of respondents in agreement with the statement
was found in the PCE user group; 22% of PCE users agreed with
the statement; and 11% of PCE users agreed strongly with the
statement. Those who were PCE users or who had considered
PCE were more than twice as likely as other groups to agree that
they might feel pressure to use PCEs.
Predictors of PCE use
Tables 10–13 present the findings from a series of ordinal
logistic regression models fitted for each of the modafinil,
methylphenidate, Adderall and caffeine user groups.
Focusing on Model VI in each of the four tables (Tables 10–13),
females and people in the youngest age group (ages 17–20) were
less likely to use modafinil, methylphenidate and Adderall (but not
caffeine) compared to males and the other age groups (condition-
ing on alcohol and cannabis use, awareness, beliefs about the
ethics of using smart drugs to improve academic performance, and
so on). White British students were more likely to use caffeine than
non-White and non-British White students, and non-British White
students were less likely than British White (and non-White)
students to use modafinil. Alcohol and cannabis use were both
positively associated with methylphenidate and with caffeine use,
but this partial association did not hold for modafinil and Adderall.
ADHD symptoms were not generally related to smart drug use,
although ADHD symptoms were a weak and positive predictor of
methylphenidate use. Awareness of other people at university
using smart drugs was strongly and positively associated with use
of modafinil and methylphenidate and moderately associated with
use of Adderall and caffeine.
Finally, we interpret the findings from multinomial logistic
regressions for each of modafinil, methylphenidate and Adderall.
The belief that it is unethical to use smart drugs to improve
academic performance increased the predicted odds of moving
from unaware to uninterested, but the same belief decreased the
predicted odds of moving from uninterested to having considered
taking the drug, and of moving from having considered taking the
drug to actually having taken it.
Discussion
This article has reported the findings from the smart drug
survey (www.thesmartdrugstudy.com), which is the first compre-
hensive national survey on cognitive enhancement among students
enrolled at UK and Irish universities. The survey investigated
cognitive enhancement in four areas: prevalence, practices,
motivations, and ethics.
We defined a ‘smart drug’ for participants in order to address
the problem of ambiguity around the concept. In order to avoid
conflation with prescription drug users, we excluded students with
prescriptions for methylphenidate, modafinil and Adderall in the
survey. We employed a dimensional approach to understanding
PCE prevalence to distinguish the level of current and ongoing use
of PCEs in the university setting from past and occasional use. A
dimensional investigation of PCE use therefore minimizes the risk
of over-estimating PCE as a current problem in university settings.
Such an approach is also a better means of evaluating the extent to
which PCE poses a risk of drug dependence, because it
differentiates occasional drug practices from sustained PCE.
Despite anecdotal reports of high rates of PCE in UK
universities, a majority of students surveyed in this study were
unaware of and/or uninterested in PCEs. Collectively, students in
these user groups made up 67% of the study sample.
PCE users were likely to be British male students nearing the
end of an undergraduate degree course or at postgraduate level.
Current users, and regular past users of methylphenidate and
Adderall made up less than 1% of the study sample, respectively.
Under 6% of students had used methylphenidate or Adderall as a
cognitive enhancer at least once. Modafinil was the most
commonly used PCE; just over 8% of the study sample had used
modafinil at least once. Modafinil was the only drug for which the
proportion of past users and current users was almost equal (4.1%
and 3.9% of the study population, respectively). Methylphenidate,
the most widely known PCE among surveyed students, was also
the substance that students were least interested in trying as a
cognitive enhancer (relative to modafinil, Adderall and caffeine).
While students have concerns about the ethics of PCE in the
university, there is little indication of strong principled disagree-
ment with PCE. In general, the level of concern about the ethics of
PCE use varied with students’ interest in and use of PCEs, with
those who had considered PCE and used PCE reporting lower
levels of ethical concern than those who were uninterested and/or
unaware. Nevertheless, our findings suggest that moral consider-
ations may be positively associated with a sustained lack of interest
among students in accessing and in using PCEs.
Concerns about peer pressure or coercion to use PCEs were
very low among all students. Interestingly, concern about coercion
grew with interest in and with personal use of PCE; we also found
that awareness of PCE use in the peer group strongly predicted
personal use. Taken together, these findings suggest that direct and
indirect peer pressure may be mechanisms by which PCE spreads
within groups in the university context. Such group dynamics
warrant further investigation, particularly as they may help to
Table 9. PCE in academia is ethically problematic (n= 877).
Unaware/uninterested
in some PCEs n (%)
Completely
unaware n (%)
Uninterested
n (%)
Considered
n (%)
Non-PCE-use
n (%) PCE-use n (%)
Strongly disagree 26 (7.8%) 16 (13.0%) 8 (6.4%) 32 (17.9%) 8 (26.7%) 32 (39.0%)
Disagree 34 (10.2%) 10 (8.1%) 5 (4.0%) 32 (17.9%) 6 (20%) 20 (24.4%)
Neutral 43 (12.8%) 16 (13.0%) 16 (12.6%) 35 (20.0%) 3 (10%) 13 (15.6.%)
Agree 108 (32.2%) 37 (30.1%) 40 (31.5%) 46 (25.7%) 7 (23.3%) 15 (18.3%)
Strongly agree 124 (37.0%) 44 (35.8%) 58 (45.7%) 34 (19.0%) 6 (20%) 2 (2.4%)
Total 335 (100%) 123 (100%) 127 (100%) 179 (100%) 30 (100%) 82 (100%)
doi:10.1371/journal.pone.0105969.t009
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explain why PCE use in certain UK universities is anecdotally
reported to be high, while PCE use across UK universities appears
to be low [11].
In line with patterns of recreational drug use, curiosity
motivated occasional PCE for those substances that were less
available to students, perhaps because the stimulant drugs were
more likely to be sourced opportunistically from friends and
family. Alcohol and cannabis use were associated with methyl-
phenidate use as a cognitive enhancer, giving some further weight
to concerns about the intersection of PCE with recreational drug
use. At the same time, methylphenidate PCE use was also weakly
associated with ADHD symptomatology, suggesting that, in a
subset of students, PCE may approach self-medication [31].
Cannabis is another substance associated with self-medication of
ADHD [32]. The relationship between use of stimulants for PCE,
ADHD symptomatology, and cannabis use is complex and
requires focused investigation.
Our findings lend themselves to at least two plausible
interpretations. One interpretation is that the data indicate
substantial resilience to PCE among UK and Irish university
students. Resilience here is defined as: low lifetime prevalence of
PCE and very low levels of consistent use of PCEs, in a setting in
which there is awareness of and interest in PCEs. Resilience has
not been well documented or described in the literature on
cognitive enhancement to date. On the basis of this study,
resilience cannot be attributed wholly to a lack of interest in
cognitive enhancement. Caffeine, delivered in tablets and energy
drinks, was reported to be a common and consistently used
cognitive enhancer. Further studies should differentiate attitudes to
cognitive enhancement and attitudes toward pharmacological
Table 10. Ordinal logistic regression predicting knowledge and use of modafinil. +
Predictors Model
‘‘
I II III IV V VI
Female (reference category: male) 0.434*** 0.435*** 0.420*** 0.414*** 0.409*** 0.450***
(26.20) (25.99) (26.17) (26.25) (26.26) (25.41)
age 21–24 (reference category: age 17–20) 2.001*** 2.017*** 1.951*** 1.919*** 1.911*** 1.982***
24.56 24.61 24.35 24.23 24.20 24.41
age 25–29 (reference category: age 17–20) 1.680* 1.682* 1.743* 1.718* 1.712* 1.670*
22.35 22.34 22.49 22.42 22.41 22.29
age 30+ (reference category: age 17–20) 2.584** 2.491** 2.758*** 2.748*** 2.751*** 2.703***
23.20 23.05 23.38 23.36 23.36 23.30
Ethnicity: not-white (reference category: British white) 1.163 1.086 1.064 1.072 1.070 1.058
20.79 20.41 20.31 20.35 20.34 20.28
Ethnicity: white but not British
(reference category: British white)
0.597** 0.588** 0.566** 0.565** 0.566** 0.558**
(22.66) (22.73) (22.89) (22.90) (22.89) (22.96)
Alcohol use
(ranges from 1/never tried to 4/use weekly or more)
0.912 0.930 0.935 0.937 0.938
(21.30) (21.01) (20.93) (20.90) (20.89)
Cannabis use
(ranges from 1/never tried to 4/use weekly or more)
1.033 0.982 0.997 0.997 0.948
20.43 (20.24) (20.04) (20.04) (20.68)
Awareness of other people at University using
smart drugs (dichotomous: no and yes)
2.048*** 2.049*** 2.054*** 1.997***
25.10 25.10 25.11 24.89
ADHD score (ranges from 0 to 6) 0.939 0.930 0.927
(21.51) (21.62) (21.70)
Self-esteem score (ranges from 0 to 30) 0.993 0.993
(20.58) (20.54)
Beliefs about the ethnics of using smart drugs to improve
academic performance (ranges from 1 to 5, where 1 means
‘strongly disagree’ and 5 means ‘strongly agree’ that
it is ‘ethically problematic’)
0.867**
(22.62)
Sample size (N) 887 887 886 886 886 886
+ Outcome variable has four mutually exclusive categories: unaware, uninterested, have considered, and have used (including currently use) each drug.
‘‘ Parameter estimates are odd-ratios, i.e. exponentiated coefficients. Standard errors in parentheses.
*** p,.001,
** p,.01,
* p,.05.
doi:10.1371/journal.pone.0105969.t010
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cognitive enhancement. Low uptake of PCE among UK and Irish
university students may reflect concerns about drugs as the means
of cognitive enhancement, rather than reflecting the desirability of
cognitive enhancement as an end [33].
Another interpretation of the survey findings focuses on the
relatively high proportion of students who showed an interest in
PCE. Students who had considered using PCEs (20.4%) and
students who had used a PCE at least once (9.4%) collectively
made up one-third of the study sample. A key question here is why
student interest in, and initial experimentation with PCE does not
convert at higher rates to current ongoing use of PCEs. One clear
answer from this survey is lack of availability of PCEs.
Upon closer examination, the data suggest a nuanced relation-
ship between availability and PCE use. Availability is likely a key
factor in different patterns of PCE use. These patterns of use are
also moderated by awareness of PCEs. We note that despite the
relatively greater availability of modafinil in the UK, it is still the
most unknown PCE relative to methylphenidate and Adderall,
with nearly 60% of students reporting that they had never heard of
it. Although students reported more difficulty accessing the
prescription stimulants, more students were past users of
methylphenidate (44 students) than past users of modafinil (36
students). However, current modafinil users exceeded current
methylphenidate users by a ratio of approximately 3:1.
The ease of internet access to modafinil is probably a factor in
the ongoing use of this drug, resulting in a relatively higher
proportion of current modafinil users despite the substantial lack of
awareness about and interest in the drug. Similarly, the lack of
availability of methylphenidate and Adderall in the UK is a
probable factor in the relatively lower rates of ongoing use of these
substances for cognitive enhancement, despite higher levels of
awareness of and interest in these drugs.
Table 11. Ordinal logistic regression predicting knowledge and use of methylphenidate. +
Predictors Model
‘‘
I II III IV V VI
Female (reference category: male) 0.445*** 0.568*** 0.562*** 0.579*** 0.559*** 0.635**
(25.99) (24.05) (24.10) (23.88) (24.09) (23.07)
age 21–24 (reference category: age 17–20) 1.513** 1.493** 1.410* 1.467* 1.451* 1.511**
22.80 22.70 22.29 22.54 22.47 22.72
age 25–29 (reference category: age 17–20) 2.069*** 1.920** 1.984** 2.030** 2.012** 1.990**
23.41 23.02 23.16 23.27 23.23 23.18
age 30+ (reference category: age 17–20) 2.400** 2.542** 3.026*** 3.033*** 3.048*** 2.960***
22.97 23.13 23.69 23.71 23.72 23.65
Ethnicity: not-white (reference category: British white) 0.664* 0.841 0.817 0.812 0.810 0.802
(22.10) (20.85) (20.98) (21.01) (21.02) (21.07)
Ethnicity: white but not British
(reference category: British white)
0.723 0.767 0.716 0.718 0.728 0.720
(21.76) (21.43) (21.79) (21.78) (21.70) (21.76)
Alcohol use
(ranges from 1/never tried to 4/use weekly or more)
1.156* 1.202* 1.198* 1.205* 1.210**
22.01 22.55 22.49 22.57 22.61
Cannabis use
(ranges from 1/never tried to 4/use weekly or more)
1.638*** 1.545*** 1.506*** 1.511*** 1.426***
26.60 25.73 25.36 25.39 24.51
Awareness of other people at University using
smart drugs (dichotomous: no and yes)
2.485*** 2.513*** 2.533*** 2.433***
26.46 26.53 26.57 26.26
ADHD score (ranges from 0 to 6) 1.151*** 1.121** 1.119*
23.39 22.58 22.53
Self-esteem score (ranges from 0 to 30) 0.978 0.979
(21.72) (21.68)
Beliefs about the ethics of using smart drugs to improve
academic performance (ranges from 1 to 5, where 1 means
‘strongly disagree’ and 5 means ‘strongly agree’ that
it is ‘ethically problematic’)
0.839**
(23.26)
Sample size (N) 887 887 886 886 886 886
+ Outcome variable has four mutually exclusive categories: unaware, uninterested, have considered, and have used (including currently use) each drug.
‘‘ Parameter estimates are odd-ratios, i.e. exponentiated coefficients. Standard errors in parentheses.
*** p,.001,
** p,.01,
* p,.05.
doi:10.1371/journal.pone.0105969.t011
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Finally, we note that these PCE use patterns might look very
different if students found PCE to make a remarkable difference in
their academic performance and achievement. We would expect
to find a higher rate of consistent PCE use under such
circumstances; more demand for, and wider availability of PCEs
in universities; and a higher likelihood of conversion from interest
to use. From the current use pattern data, we infer that students
who use PCEs are not finding them to make a remarkable
difference to their academic progress.
Limitations
As noted above, this survey was not based on a random sample.
Results of convenience sample surveys may be biased, due to
participant self-selection and other factors. We used an on-line
survey tool rather than traditional survey approaches, which were
considered too costly and unfeasible due to access and adminis-
tration barriers. On-line surveys can have advantages compared to
paper-based surveys [34], including ease of access and guaranteed
anonymity.
We were unable to conduct extensive reliability and validity
tests of individual survey questions, beyond the efforts outlined in
the methods section. Methodological inconsistency is a major
barrier to comparisons of PCE studies across and within countries.
We hope that transparent publication of our methods and findings
on the survey website will enable further testing of the questions as
well as more consistency among future surveys of PCE.
Conclusion
In May, 2014 the BBC reported that the UK Advisory Council
on the Misuse of Drugs would carry out a review of ‘smart drug
Table 12. Ordinal logistic regression predicting knowledge and use of Adderall. +
Predictors Model
‘‘
I II III IV V VI
Female (reference category: male) 0.520*** 0.582*** 0.581*** 0.591*** 0.568*** 0.450***
(25.05) (24.04) (24.04) (23.90) (24.14) (25.41)
age 21–24 (reference category: age 17–20) 1.295 1.298 1.274 1.293 1.285 1.982***
21.80 21.81 21.68 21.77 21.73 24.41
age 25–29 (reference category: age 17–20) 1.267 1.216 1.243 1.256 1.250 1.670*
21.15 20.95 21.05 21.10 21.08 22.29
age 30+ (reference category: age 17–20) 0.740 0.715 0.771 0.771 0.778 2.703***
(20.98) (21.08) (20.83) (20.83) (20.80) 23.300
Ethnicity: not-white (reference category: British white) 1.155 1.155 1.136 1.132 1.127 1.058
20.78 20.75 20.66 20.64 20.62 20.28
Ethnicity: white but not British
(reference category: British white)
1.185 1.192 1.157 1.164 1.174 0.558**
20.96 20.99 20.82 20.85 20.90 (22.96)
Alcohol use
(ranges from 1/never tried to 4/use weekly or more)
0.927 0.943 0.940 0.945 0.938
(21.10) (20.85) (20.88) (20.82) (20.89)
Cannabis use
(ranges from 1/never tried to 4/use weekly or more)
1.283*** 1.237** 1.223** 1.228** 0.948
23.47 22.94 22.76 22.81 (20.68)
Awareness of other people at University
using smart drugs (dichotomous: no and yes)
1.627*** 1.634*** 1.645*** 1.997***
23.68 23.71 23.75 24.89
ADHD score (ranges from 0 to 6) 1.069 1.039 0.927
21.65 20.88 (21.70)
Self-esteem score (ranges from 0 to 30) 0.976 0.993
(21.94) (20.54)
Beliefs about the ethics of using smart drugs to improve
academic performance (ranges from 1 to 5, where 1 means
‘strongly disagree’ and 5 means ‘strongly agree’ that
it is ‘ethically problematic’)
0.867**
(22.62)
Sample size (N) 887 887 886 886 886 886
+ Outcome variable has four mutually exclusive categories: unaware, uninterested, have considered, and have used (including currently use) each drug.
‘‘ Parameter estimates are odd-ratios, i.e. exponentiated coefficients. Standard errors in parentheses.
*** p,.001,
** p,.01,
* p,.05.
doi:10.1371/journal.pone.0105969.t012
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use’ (www.news.live.bbc.co.uk/newsbeat/27207469). Our re-
search represents the most comprehensive survey of PCE to date
among UK and Irish university students. We found a mixed
picture of high ‘resilience’ combined with relatively high interest in
PCE. Lifetime prevalence of PCE using modafinil, methylpheni-
date or Adderall was 9.4%; past regular and current PCE users of
these substances made up between 0.3%–4% of the survey
population. PCE users were more likely to be male, older and
British; and they were very likely to be aware of other PCE users.
ADHD symptomatology was weakly correlated with use of
methylphenidate for PCE. Principled ethical disagreement with
PCE was low; those students who thought PCE was unethical were
less likely to develop an interest in, or desire to access PCE. Use of
stimulants and modafinil for non-PCE purposes was low; however,
alcohol and cannabis use predicted PCE.
The present study suggests two simultaneous paths for
universities to take in relation to PCE: monitoring and education.
UK and Irish universities should discuss reasons and strategies to
monitor PCE availability and circulation. On the basis of this
study, we feel it would be unreasonable for universities to institute
drastic monitoring measures, because students show themselves to
be sufficiently resilient to PCE without direct intervention.
Moreover, university student life is ideally characterised by
increasing autonomy and responsibility; these values should not
be undermined through PCE surveillance activities.
Universities should take account of the level of interest in
cognitive enhancement and educate students to make responsible
decisions about PCEs. We recognise that ‘responsible’ decision-
making in relation to misuse of prescription drugs, could be taken
to mean that in all cases students should not misuse such drugs for
PCE. However, we favour a pragmatic approach in which
Table 13. Ordinal logistic regression predicting knowledge and usage of caffeine. +
Predictors Model
‘‘
I II III IV V VI
Female (reference category: male) 0.731* 0.944 0.929 0.935 0.904 1.059
(22.41) (20.42) (20.53) (20.48) (20.72) 20.39
age 21–24 (reference category: age 17–20) 1.131 1.109 1.069 1.075 1.063 1.110
20.86 20.70 20.45 20.48 20.41 20.70
age 25–29 (reference category: age 17–20) 1.354 1.242 1.244 1.247 1.237 1.209
21.41 20.99 21.00 21.01 20.97 20.85
age 30+ (reference category: age 17–20) 0.729 0.801 0.852 0.854 0.849 0.810
(21.05) (20.72) (20.52) (20.51) (20.53) (20.67)
Ethnicity: not-white (reference category: British white) 0.417*** 0.549** 0.540** 0.539** 0.538** 0.519**
(24.67) (23.00) (23.08) (23.09) (23.10) (23.26)
Ethnicity: white but not British
(reference category: British white)
0.514*** 0.549*** 0.536*** 0.537*** 0.540*** 0.523***
(23.79) (23.34) (23.45) (23.44) (23.40) (23.56)
Alcohol use
(ranges from 1/never tried to 4/use weekly or more)
1.265** 1.290*** 1.288*** 1.296*** 1.302***
23.27 23.51 23.50 23.57 23.61
Cannabis use
(ranges from 1/never tried to 4/use weekly or more)
1.659*** 1.606*** 1.595*** 1.603*** 1.492***
26.33 25.87 25.75 25.79 24.79
Awareness of other people at University using
smart drugs (dichotomous: no and yes)
1.557** 1.556** 1.574*** 1.492**
23.27 23.26 23.34 22.92
ADHD score (ranges from 0 to 6) 1.030 1.003 1.000
20.71 20.07 0.00
Self-esteem score (ranges from 0 to 30) 0.978 0.979
(21.70) (21.67)
Beliefs about the ethics of using smart drugs to improve
academic performance (ranges from 1 to 5, where 1 means
‘strongly disagree’ and 5 means ‘strongly agree’ that
it is ‘ethically problematic’)
0.809***
(23.86)
Sample size (N) 887 887 886 886 886 886
+ Outcome variable has four mutually exclusive categories: unaware, uninterested, have considered, and have used (including currently use) each drug.
‘‘ Parameter estimates are odd-ratios, i.e. exponentiated coefficients. Standard errors in parentheses.
*** p,.001,
** p,.01,
* p,.05.
doi:10.1371/journal.pone.0105969.t013
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‘responsible decision-making’ is characterised by raising awareness
of the ethics, risks and benefits of pharmacological means of
cognitive enhancement, relative to other means. As part of this
endeavour, universities should focus on deflating the media hype
around PCE and correcting the wrong impression that sustained
use of ‘smart drugs’ is highly prevalent among UK students.
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